Compare · CLLS vs CLXT
CLLS vs CLXT
Side-by-side comparison of Cellectis S.A. (CLLS) and Calyxt Inc. (CLXT): market cap, price performance, sector, and recent activity on the wire.
Summary
- CLLS operates in Health Care, while CLXT operates in Industrials - the two are in different parts of the market.
- CLLS is the larger of the two at $264.4M, about 4.3x CLXT ($62.0M).
- CLLS has hit the wire 5 times in the past 4 weeks while CLXT has been quiet.
- CLLS has more recent analyst coverage (9 ratings vs 2 for CLXT).
- Company
- Cellectis S.A.
- Calyxt Inc.
- Price
- -
- -
- Market cap
- $264.4M
- $62.0M
- 1M return
- -14.56%
- -
- 1Y return
- +45.86%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Agricultural Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2017
- News (4w)
- 5
- 0
- Recent ratings
- 9
- 2
Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.
Calyxt Inc.
Calyxt, Inc., a technology company, focuses on delivering plant-based solutions in the United States. It engages in the development of improved digestibility alfalfa; high fiber wheat; high oleic low linolenic soybeans; winter oats; hemp; fat soybeans; and cold storable potatoes. As of March 4, 2021, the company had nine projects at Phase I stage or later in development across alfalfa, hemp, oats, soybeans, and wheat. Calyxt, Inc. has a research collaboration with NRGene, which includes the adoption of NRGene's cloud-based genomics platform to support various research projects; and a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and various geographies outside the United States. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
Latest CLLS
- Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
- Amendment: SEC Form 6-K/A filed by Cellectis S.A.
- SEC Form 6-K filed by Cellectis S.A.
- SEC Form 6-K filed by Cellectis S.A.
- Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
- SEC Form 6-K filed by Cellectis S.A.
- Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
- SEC Form 6-K filed by Cellectis S.A.
- Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
- Barclays initiated coverage on Cellectis with a new price target
Latest CLXT
- Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer
- SEC Form SC 13G/A filed by Calyxt Inc. (Amendment)
- Calyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Riggs Rory B converted options into 1,500,000 shares and acquired 1,505,967 units of Class B Common Stock, increasing direct ownership by 128% to 3,103,788 units (SEC Form 4)
- Calyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Calyxt Inc.
- Calyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)
- Calyxt Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Calyxt Inc.